Seoane Joan, De Mattos-Arruda Leticia
Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain; Institució Catalana de Recerca I Estudis Avançats (ICREA), Barcelona, Spain.
Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain.
Mol Oncol. 2014 Sep 12;8(6):1120-31. doi: 10.1016/j.molonc.2014.05.009. Epub 2014 Jun 2.
Brain metastasis is a devastating complication of cancer with unmet therapeutic needs. The incidence of brain metastasis has been rising in cancer patients and its response to treatment is limited due to the singular characteristics of brain metastasis (i.e., blood-brain-barrier, immune system, stroma). Despite improvements in the treatment and control of extracranial disease, the outcomes of patients with brain metastasis remain dismal. The mechanisms that allow tumor cells to promulgate metastases to the brain remain poorly understood. Further work is required to identify the molecular alterations inherent to brain metastasis in order to identify novel therapeutic targets and explicate the mechanisms of resistance to systemic therapeutics. In this article, we review current knowledge of the unique characteristics of brain metastasis, implications in therapeutic resistance, and the possibility of developing biomarkers to rationally guide the use of targeted agents.
脑转移是癌症的一种毁灭性并发症,存在未满足的治疗需求。癌症患者中脑转移的发生率一直在上升,由于脑转移的独特特征(即血脑屏障、免疫系统、基质),其对治疗的反应有限。尽管颅外疾病的治疗和控制有所改善,但脑转移患者的预后仍然很差。肿瘤细胞向脑扩散转移的机制仍知之甚少。需要进一步开展工作来确定脑转移所固有的分子改变,以便识别新的治疗靶点并阐明对全身治疗产生耐药性的机制。在本文中,我们综述了关于脑转移独特特征的现有知识、其在治疗耐药性方面的影响,以及开发生物标志物以合理指导靶向药物使用的可能性。